Impact of methylation of the p16INK4a gene on the prognosis ofhead and neck squamous cell carcinoma patients.
10.5125/jkaoms.2012.38.2.101
- Author:
Eui Hoon LEE
1
;
Dae Seok HWANG
;
Sang Hun SHIN
;
Uk Kyu KIM
;
In Kyo CHUNG
;
Yong Deok KIM
Author Information
1. Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University, Yangsan, Korea. ydkimdds@pusan.ac.kr
- Publication Type:Original Article
- Keywords:
Methylation;
Epigenomics;
Prognosis;
Neoplasms
- MeSH:
Carcinoma, Squamous Cell;
Cell Cycle;
Cell Cycle Checkpoints;
Cyclin-Dependent Kinases;
Epigenomics;
Genes, p16;
Genes, Retinoblastoma;
Genes, Tumor Suppressor;
Head;
Humans;
Loss of Heterozygosity;
Methylation;
Neck;
Phosphorylation;
Point Mutation;
Prognosis;
Recurrence;
S Phase;
Smoke;
Smoking
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2012;38(2):101-109
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: The inactivation of the tumor suppressor gene p16INK4a plays an important role in the development of malignant tumors, including oral squamous cell carcinoma. The p16 gene is involved in the p16/cyclin-dependent kinase/retinoblastoma (Rb) gene pathway of cell cycle control. The p16 protein is considered a negative regulator of this pathway. The p16 gene encodes an inhibitor of cyclin-dependent kinases 4 and 6 which regulate the phosphorylation of the retinoblastoma gene and G1 to S phase transition in the cell cycle. However, the p16 gene can lose its functionality through point mutations, loss of heterozygosity or methylation of its promoter region. MATERIALS AND METHODS: In this study, the authors analyzed the correlation between various clinicopathological findings-patient age, gender and smoking, disease recurrence, tumor size, stage, and differentiation- and p16 protein expression or p16 promoter hypermethylation in 59 cases of head and neck squamous cell carcinoma. RESULTS: The results revealed p16 protein expression and p16 promoter hypermethylation in 28 cases (47.5%) and 21 cases (35.6%), respectively, of head and neck squamous cell carcinoma. However, neither p16 protein expression nor p16 promoter hypermethylation had any statistical influence on clinicopathological findings or survival rate. CONCLUSION: This data, and a review of the literature, suggest that p16 promoter hypermethylation cannot yet be used as an independent prognostic factor influencing carcinogenesis, but must be considered as an important factor along with other genetic alterations affecting the pRb pathway.
